PolyPid
Petach Tikva · Israel corporation · 1 known investors
Find your way into PolyPid
326 people in our graph share verified history with the PolyPid team — schools, employers, funds. One of them is your warm intro.
Assaf Arakiunlockedknows Ori Warshavsky · together at Ben-Gurion University of the Negev (overlapped)
×2knows the team · via Duke University - The Fuqua School of Business
×3knows the team · via London Business School
×4knows the team · via The Hebrew University of Jerusalem
knows the team · via Duke University, Office of Licensing and Ventures
knows the team · via Hebrew University of Jerusalem
PolyPid is a biopharmaceutical company developing long-acting, controlled-release medicines delivered at the site of care, with a lead product D-PLEX100 using its proprietary Kynatrix technology for preventing surgical site infections. Its pipeline targets surgical care, metabolic diseases, and other therapeutic areas.
Founders & leadership
NE
Noam EmanuelinCEO & Founder2008–2010Noam Emanuel is a biologist and drug-delivery scientist who founded PolyPid and served as its first CEO and Chief Scientific Officer, leading development of the PLEX platform and D-PLEX100 for surgical site infection prevention through Phase 3 clinical trials and FDA Breakthrough Therapy Designation. He has advised biotech investors and currently works on decision-making strategy in biotechnology and innovation.
AW
Amir WeisberginCo-founder · CEO
DC
Dikla Czaczkes AkselbradinChief Executive Officer and Board Member
OW
Ori WarshavskyinChief Operating Officer - US OperationsOri Warshavsky is Chief Operating Officer for US Operations at PolyPid, a biopharmaceutical company developing controlled-release drug delivery technologies. He brings over 15 years of experience in biotech and pharma across engineering, science, marketing, business development, and investor relations.
JH
Jacob HarelNamed on SEC filing
YB
Yossi BenAmramNamed on SEC filing
IK
Itzhak KrinskyNamed on SEC filing
RB
ND
Nir DrorNamed on SEC filing
YB
Yechezkel BarenholzNamed on SEC filing
NT
Nurit Tweezer-ZaksinChief Medical Officer
DH
Dalit HazanNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$125.4M disclosed across 6 rounds · 2016–2025
▶$26.7MraisedJun 2025 · 20 investors · BiotechnologyRule 506(b)
▶$26.7MraisedJun 2025 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nurit Tweezer-ZaksDirector
- Ori WarshavskyExecutive Officer
- Yitzchak JacobovitzDirector
- Jonny MissulawinExecutive Officer
- Nir DrorDirector
- Jacob HarelDirector
- Itzhak KrinskyDirector
- Robert B. SteinDirector
- Dalit HazanExecutive Officer
- Yechezkel BarenholzDirector
- Yossi BenAmramDirector
- Dikla Czaczkes AkselbradExecutive Officer
- Offering amount
- $26.7M
- Amount sold
- $26.7M
- First sale
- Jun 2025
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$14.5MraisedJan 2025 · 12 investors · BiotechnologyRule 506(b)
▶$14.5MraisedJan 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacob HarelDirector
- Nir DrorDirector
- Itzhak KrinskyDirector
- Nurit Tweezer-ZaksDirector
- Yossi BenAmramDirector
- Yechezkel BarenholzDirector
- Ori WarshavskyExecutive Officer
- Dalit HazanExecutive Officer
- Robert B. SteinDirector
- Dikla Czaczkes AkselbradExecutive Officer
- Jonny MissulawinExecutive Officer
- Offering amount
- $14.5M
- Amount sold
- $14.5M
- Sales commissions
- $1M
- Placement agents
- CITIZENS JMP SECURITIES, LLC
- First sale
- Dec 2024
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$14.2MraisedAug 2024 · 17 investors · BiotechnologyRule 506(b)
▶$14.2MraisedAug 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacob HarelDirector
- Yossi BenAmramDirector
- Itzhak KrinskyDirector
- Dikla Czaczkes AkselbradExecutive Officer
- Robert B. SteinDirector
- Nir DrorDirector
- Yechezkel BarenholzDirector
- Ori WarshavskyExecutive Officer
- Nurit Tweezer-ZaksDirector
- Dalit HazanExecutive Officer
- Jonny MissulawinExecutive Officer
- Offering amount
- $14.2M
- Amount sold
- $14.2M
- Sales commissions
- $484.2K
- Placement agents
- CITIZENS JMP SECURITIES, LLC
- First sale
- Aug 2024
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$35MraisedJan 2024 · 20 investors · BiotechnologyRule 506(b)
▶$35MraisedJan 2024 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacob HarelDirector
- Itzhak KrinskyDirector
- Nurit Tweezer-ZaksDirector
- Ori WarshavskyExecutive Officer
- Yossi BenAmramDirector
- Dalit HazanExecutive Officer
- Nir DrorDirector
- Robert B. SteinDirector
- Jonny MissulawinExecutive Officer
- Dikla Czaczkes AkselbradExecutive Officer, Director
- Yechezkel BarenholzDirector
- Offering amount
- $35M
- Amount sold
- $35M
- Sales commissions
- $1.1M
- Placement agents
- CITIZENS JMP SECURITIES, LLC
- First sale
- Jan 2024
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$26.9MraisedSep 2019 · 361 investors · BiotechnologyRule 506(b)
▶$26.9MraisedSep 2019 · 361 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Noam EmanuelExecutive Officer, Director
- Shaul MukhtarExecutive Officer
- Dalit HazanExecutive Officer, Director
- Jacob HarelDirector
- Eli FrydmanDirector
- Chaim HurvitzDirector
- Anat Tsour SegalExecutive Officer, Director
- Itzhak KrinskyDirector
- Gerry RubensDirector
- Dikla Czaczkes AkselbradExecutive Officer
- Amir WeisbergExecutive Officer, Director
- Yechezkel BarenholzDirector
- Offering amount
- $50M
- Amount sold
- $26.9M
- Minimum investment
- $50K
- Sales commissions
- $2.7M
- Proceeds to insiders
- $687.2K
- Placement agents
- National Securities Corporation
- First sale
- Jun 2019
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$8.1MraisedFeb 2016 · 8 investors · BiotechnologyRule 506(b)
▶$8.1MraisedFeb 2016 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Noam EmanuelExecutive Officer, Director
- Amir WeisbergExecutive Officer, Director
- Eitan KyietExecutive Officer, Director
- Dikla Czaczkes AkselbradExecutive Officer
- Shaun MarcusExecutive Officer
- Offering amount
- $8.7M
- Amount sold
- $8.1M
- First sale
- Feb 2016
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
TradingView7 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Seeking Alpha7 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood6 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall St6 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies competing with PolyPid for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does PolyPid do?
- PolyPid is a biopharmaceutical company developing long-acting, controlled-release medicines delivered at the site of care, with a lead product D-PLEX100 using its proprietary Kynatrix technology for preventing surgical site infections. Its pipeline targets surgical care, metabolic diseases, and other therapeutic areas.
- Who founded PolyPid?
- PolyPid was founded by Noam Emanuel, Amir Weisberg.
- Who are PolyPid's investors?
- PolyPid's investors include Xenia Venture Capital.
- How much funding has PolyPid raised?
- PolyPid has disclosed $125.4M raised across 6 rounds.
- Where is PolyPid headquartered?
- PolyPid is headquartered in Petach Tikva.